10-Q: NovoCure Reports Increased Losses Amid Revenue Growth

NovoCure Limited reported an 8% increase in net revenues for Q3 2025, reaching $167.2 million, but saw net losses widen to $37.3 million and Adjusted EBITDA turn negative.

Summary

• Net revenues for the three months ended September 30, 2025, increased by 8% to $167.2 million, up from $155.1 million in the same period of 2024.
• Net loss for Q3 2025 widened to $37.3 million, compared to a net loss of $30.6 million in Q3 2024.
• Adjusted EBITDA for Q3 2025 was a loss of $3.0 million, a decrease from a profit of $1.7 million in Q3 2024.
• Gross margin decreased to 73% in Q3 2025 from 77% in Q3 2024, primarily due to higher array costs, new array roll-out, NSCLC launch, and increased tariffs.
• Total active patients on therapy increased by 7% to 4,416 as of September 30, 2025, compared to 4,113 at September 30, 2024.
• The company presented positive results from the Phase 3 PANOVA-3 clinical trial for pancreatic cancer and filed a PMA application for Optune Pax.
• Final data from the Phase 3 METIS clinical trial for brain metastases from NSCLC showed statistically significant improvement in time to intracranial progression, with a PMA application for Optune Mya underway.
• The Phase 2 LUNAR-4 trial for metastatic NSCLC was terminated due to the availability of real-world evidence, not safety concerns.
• NovoCure drew Tranche B of its senior secured credit facility, adding $100.0 million to its long-term debt, bringing the total borrowed to $200.0 million.
• The company's $560.9 million aggregate principal amount of 0% Convertible Senior Notes are due to mature on November 1, 2025.

Sentiment

Score: 4

Explanation: While the company shows strong clinical progress and revenue growth, the widening net losses, negative Adjusted EBITDA, and declining gross margin indicate financial deterioration. The upcoming convertible note maturity and potential capital needs add a layer of financial risk, offsetting the positive clinical developments.

Positives

• Net revenues increased by 8% for both the three and nine months ended September 30, 2025, demonstrating continued commercial growth.
• Active patient count grew by 7% year-over-year to 4,416, indicating increased adoption of TTFields therapy.
• Positive results from the Phase 3 PANOVA-3 clinical trial for pancreatic cancer, showing improved median overall survival (16.2 months vs 14.2 months) and pain-free survival (15.2 months vs 9.1 months).
• Statistically significant improvements in quality of life measures for pancreatic cancer patients treated with TTFields therapy in the PANOVA-3 trial.
• Positive final data from the Phase 3 METIS clinical trial for brain metastases from NSCLC, meeting its primary endpoint with a 28% risk reduction in time to intracranial progression.
• Regulatory progress with the filing of a PMA application for Optune Pax for pancreatic cancer and the modular PMA shell approval for Optune Mya for brain metastases.
• Expansion of international market access, including coverage for newly diagnosed GBM in Spain.
• Successful draw of Tranche B of the senior secured credit facility, providing an additional $100.0 million in funding.

Negatives

• Net loss widened to $37.3 million in Q3 2025 from $30.6 million in Q3 2024, and to $111.7 million for the nine months ended September 30, 2025, from $102.7 million in the prior year.
• Adjusted EBITDA shifted from a profit of $1.7 million in Q3 2024 to a loss of $3.0 million in Q3 2025, indicating deteriorating operational profitability.
• Gross margin decreased to 73% in Q3 2025 from 77% in Q3 2024, primarily due to higher array costs, new product launches, and increased tariffs.
• Cost of revenues increased by 26% in Q3 2025, outpacing revenue growth, partly due to a $2.9 million inventory obsolescence provision for Optune Lua arrays.
• Financial income (expenses), net, decreased by 43% in Q3 2025, mainly due to lower interest income and increased foreign exchange expenses.
• Accumulated deficit increased to $1,265.9 million as of September 30, 2025.
• Operating expenses increased by 4% in Q3 2025, driven by higher product development, regulatory expenses, and general and administrative costs.

Risks

• The conflict in Israel poses a risk to the supply chain, particularly for single-source suppliers, despite increased stock levels and efforts to secure second-source suppliers.
• Increased U.S. tariff rates on imported goods could lead to an estimated $5 million increase in import duties in 2025, impacting cost structure.
• A prolonged U.S. government shutdown could delay FDA reviews for Optune Pax and Optune Mya PMA applications, as well as hinder CMS claims processing and Medicare reimbursements.
• The company expects operating expenses to continue increasing and potentially outpace gross profit, necessitating additional capital raises to fund operations.
• The $560.9 million Convertible Senior Notes mature on November 1, 2025, requiring a significant cash outflow.
• Gross margins are expected to continue being impacted by current and future product enhancements and the changing tariff landscape.
• The FDA has raised questions regarding the second module of the Optune Mya PMA application, which could delay the final module filing and overall approval.

Future Outlook

The company anticipates continued increases in operating expenses over the next several years, potentially outpacing gross profit, as it prepares to expand into additional indications beyond CNS and Lung. It plans to expand its clinical pipeline to study TTFields therapy for more solid tumor indications and in combination with other cancer treatments. The company expects to file the third and final module for the Optune Mya PMA application before the end of 2025, subject to resolving FDA questions on the second module. Management believes current cash and investments are sufficient for at least the next 12 months, but acknowledges the need for potential additional capital to fund operations.

Management Comments

• We believe our cash, cash equivalents and short-term investments as of September 30, 2025 are sufficient for our operations for at least the next 12 months based on our existing business plan and our ability to control the timing of significant expense commitments.
• We expect that our operating expenses will continue to increase over the next several years and may outpace our gross profit as we prepare to expand into additional indications beyond CNS and Lung.
• We intend to take actions that prioritize growth and maintain financial health and flexibility as we position our company for future profitability.

Industry Context

NovoCure operates in the highly competitive oncology medical device sector, focusing on Tumor Treating Fields (TTFields) therapy. The positive clinical trial results for pancreatic cancer (PANOVA-3) and brain metastases (METIS) position the company for potential expansion into significant new indications, which could broaden its market reach beyond glioblastoma, NSCLC, and MPM. The termination of the LUNAR-4 trial, driven by the availability of real-world evidence, reflects an industry trend towards leveraging real-world data for clinical development and market access. The company's efforts to diversify its supply chain and manage tariff impacts are critical in the current global economic and geopolitical climate, common challenges for medical device manufacturers with international operations.

Comparison to Industry Standards

• The median overall survival of 16.2 months for pancreatic cancer patients treated with TTFields therapy plus gemcitabine and nab-paclitaxel in PANOVA-3 compares favorably to historical benchmarks for locally advanced, unresectable pancreatic adenocarcinoma, which often show median survival rates in the range of 10-14 months with standard chemotherapy alone. For example, studies like the MPACT trial (gemcitabine + nab-paclitaxel) reported median overall survival of 8.5 months for metastatic pancreatic cancer, while locally advanced cases might see slightly longer. The 2-month improvement over the control arm (14.2 months) is clinically meaningful in this aggressive cancer.
• The METIS trial's demonstration of a statistically significant improvement in time to intracranial progression (median 15.0 months vs 7.5 months for control) for NSCLC patients with brain metastases following stereotactic radiosurgery represents a significant advance. Current standard of care often focuses on local control with radiation, and delaying intracranial progression is a key unmet need. This result suggests TTFields therapy could become an important adjunct in managing brain metastases, a common and debilitating complication of NSCLC.

Management Changes

Corporate Governance

Legal Proceedings

• The company is involved in various legal proceedings, claims, investigations, and litigation that arise in the ordinary course of business. Management believes the ultimate disposition of these actions will not materially affect its consolidated financial position or results of operations.

Related Party Transactions

• Sales to Zai Lab (Shanghai) Co., Ltd. under the License and Collaboration Agreement totaled $3.3 million for the three months ended September 30, 2025, and $9.8 million for the nine months ended September 30, 2025.

Stakeholder Impact

• Shareholders: Face increased net losses and a negative Adjusted EBITDA, potentially impacting share value, but benefit from positive clinical trial results that could drive future growth. The upcoming convertible note maturity represents a significant financial event.
• Patients: Benefit from expanded access to TTFields therapy in new geographies (e.g., Spain) and the potential for new indications (pancreatic cancer, brain metastases) based on positive clinical trial data.
• Employees: Continue to participate in share-based compensation plans (2024 Omnibus Incentive Plan, 2025 ESPP), aligning their interests with company performance.
• Suppliers: The company's efforts to increase stock levels and diversify its supply chain due to geopolitical risks (Israel conflict) may lead to new opportunities for alternative suppliers.
• Creditors: The company has drawn on its senior secured credit facility and faces the maturity of its convertible notes, impacting its debt profile and repayment obligations.

Next Steps

• Resolve FDA questions regarding the second module of the Optune Mya PMA application.
• File the third and final module for the Optune Mya PMA application before the end of 2025.
• Pursue regulatory approvals for Optune Pax for pancreatic cancer.
• Continue to advance ongoing clinical trials: Phase 3 TRIDENT and KEYNOTE D58 (GBM), Phase 3 LUNAR-2 (NSCLC), and Phase 2 PANOVA-4 (pancreatic cancer).
• Expand the clinical pipeline to study TTFields therapy for additional solid tumor indications and in combination with other cancer treatment modalities.
• Actively pursue coverage policies with payers to expand access to Optune Lua for NSCLC and MPM.
• Continue evaluating opportunities to expand international footprint.
• Manage the maturity of the $560.9 million Convertible Senior Notes on November 1, 2025.
• Implement actions to prioritize growth and maintain financial health and flexibility.

Key Dates

Recommendation

While NovoCure demonstrates strong clinical progress with positive Phase 3 trial results for pancreatic cancer and brain metastases, indicating significant future market potential, the current financial performance is concerning. Widening net losses, a negative Adjusted EBITDA, and a declining gross margin suggest operational challenges. The upcoming maturity of $560.9 million in convertible notes presents a substantial near-term financial obligation. For existing investors, holding the stock allows for participation in the potential upside from new indications and regulatory approvals, while acknowledging the financial headwinds. New investors might consider waiting for clearer signs of improved profitability and successful management of the debt maturity before initiating a position.

Keywords

NovoCure, TTFields, Optune Gio, Optune Lua, Glioblastoma, NSCLC, MPM, Pancreatic Cancer, Brain Metastases, Oncology, Medical Device, SEC Filing, 10-Q, Clinical Trials, PANOVA-3, METIS, FDA Approval, Financial Results